Literature DB >> 23857310

A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs.

Michele Poletti1, Chiara Logi, Claudio Lucetti, Paolo Del Dotto, Filippo Baldacci, Andrea Vergallo, Martina Ulivi, Simone Del Sarto, Giuseppe Rossi, Roberto Ceravolo, Ubaldo Bonuccelli.   

Abstract

The current study aimed at establishing the prevalence of impulse control disorders (ICDs) in patients with Parkinson disease (PD) and their association with demographic, drug-related, and disease-related characteristics. We performed a single-center cross-sectional study of 805 PD patients. Impulse control disorders were investigated with the Questionnaire for Impulsive Compulsive Disorders in Parkinson's Disease; also comorbid neuropsychiatric complications (dementia, delusions, visual hallucinations) were investigated with clinical interviews and ad hoc instruments (Parkinson Psychosis Questionnaire and Neuropsychiatry Inventory). Impulse control disorders were identified in 65 patients (prevalence, 8.1%), with pathological gambling and hypersexuality the most frequent. Impulse control disorders were present in 57 of 593 cognitively preserved patients (prevalence, 9.6%) and in 8 of 212 demented patients (prevalence, 3.8%). Impulse control disorders were significantly associated with dopamine agonists (odds ratio [OR], 5.50; 95% confidence interval [CI], 2.60-12.46; P < 0.0001) and levodopa (OR, 2.43; 95% CI, 1.06-6.35; P = 0.034). Impulse control disorders frequency was similar for pramipexole and ropinirole (16.6% vs 12.5%; OR, 1.45; 95% CI, 0.79-2.74; P = 0.227). Additional variables associated with ICDs were male sex and younger age. These findings suggested that dopaminergic treatments in PD are associated with increased odds of having an ICD, but also other demographic and clinical variables are associated with ICDs, suggesting the multifactorial nature of the ICD phenomenon in PD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23857310     DOI: 10.1097/JCP.0b013e3182979830

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  25 in total

1.  Clozapine use for refractory impulse control disorders in Parkinson's disease: a case report.

Authors:  Nicolas A Bonfils; Amine Benyamina; Henri-Jean Aubin; Amandine Luquiens
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

Review 2.  Psychiatric issues in cognitive impairment.

Authors:  Dag Aarsland; John-Paul Taylor; Daniel Weintraub
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

3.  Machine Learning-Based Prediction of Impulse Control Disorders in Parkinson's Disease From Clinical and Genetic Data.

Authors:  Johann Faouzi; Samir Bekadar; Fanny Artaud; Alexis Elbaz; Graziella Mangone; Olivier Colliot; Jean-Christophe Corvol
Journal:  IEEE Open J Eng Med Biol       Date:  2022-05-27

Review 4.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 5.  Does the Country Make a Difference in Impulse Control Disorders? A Systematic Review.

Authors:  Paloma Parra-Díaz; Juan Luis Chico-García; Álvaro Beltrán-Corbellini; Fernando Rodríguez-Jorge; Clara Lastras Fernández-Escandón; Araceli Alonso-Cánovas; Juan Carlos Martínez-Castrillo
Journal:  Mov Disord Clin Pract       Date:  2020-12-21

Review 6.  Neural and behavioral substrates of subtypes of Parkinson's disease.

Authors:  Ahmed A Moustafa; Michele Poletti
Journal:  Front Syst Neurosci       Date:  2013-12-24

Review 7.  Risk factors of impulsive-compulsive behaviors in PD patients: a meta-analysis.

Authors:  Lanxiao Cao; Tian Xu; Gaohua Zhao; Dayao Lv; Jinyu Lu; Guohua Zhao
Journal:  J Neurol       Date:  2021-08-09       Impact factor: 4.849

8.  Co-occurrence of apathy and impulse control disorders in Parkinson disease.

Authors:  Bonnie M Scott; Robert S Eisinger; Matthew R Burns; Janine Lopes; Michael S Okun; Aysegul Gunduz; Dawn Bowers
Journal:  Neurology       Date:  2020-10-01       Impact factor: 9.910

Review 9.  Approach to Cognitive Impairment in Parkinson's Disease.

Authors:  Qiang Zhang; Georgina M Aldridge; Nandakumar S Narayanan; Steven W Anderson; Ergun Y Uc
Journal:  Neurotherapeutics       Date:  2020-11-17       Impact factor: 6.088

10.  Orthostatic stability with intravenous levodopa.

Authors:  Shan H Siddiqi; Mary L Creech; Kevin J Black
Journal:  PeerJ       Date:  2015-08-27       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.